DMAC   $4.18  3.98% Market Closed

DiaMedica Therapeutics Inc
Last Events:

2023-08-09 Signal in RSI changed from bearish recovery to bearish weakening. RSI indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: exit from the overbought zone.

2023-08-09 Signal in EMA100 changed from bearish reversal to bullish reversal. The price is trying to cross up the moving average line If the intersection will be successful, then an upside trend can be formed.

2023-08-06 Trend pattern changed from расходящийся клин с наклоном вверх to канал.

2023-08-06 Signal in EMA100 changed from bullish reversal to bearish reversal. The price is trying to cross down the moving average line If the intersection will be successful, then a downside trend can be formed.

2023-08-06 Trend changed from turning up to flat and up.

2023-08-05 Signal in Stochastic changed from bullish to bearish. The stochastic indicator is in the lower part of the neutral territory and it falls. These factors indicate that negative dynamics persists. Last signal: signal line crossed the middle level.

2023-08-03 Signal in Stochastic changed from bullish reversal to bullish. The stochastic indicator is in the upper part of the neutral territory and it grows. These factors indicate that positive dynamics persists. Last signal: up-crossing the middle level.

2023-08-03 Signal in RSI changed from bearish weakening to bearish recovery. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.


Current temperature: 13.49
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 4
Target Price Mean 7.00
Mean unverified/preliminary 7.00 / 7.00
Target Price Low / High 6.00 / 8.00
Median / STD DEV 7.00 / 0.82
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Buy ActivelyBuy ActivelyBuy
rsi ActivelyBuy ActivelyBuy None
macd None None None
stoch None None None
ma20 ActivelyBuy ActivelyBuy ActivelyBuy
ma50 None None None
ma100 Buy ActivelyBuy None
Candlestick PatternOct. 23, 2024 Three Stars -
ISIN CA25253X2077
ceo Mr. Dietrich John Pauls MBA
Website https://www.diamedica.com
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.